Evaluation of IGRA, Symptoms and Chest Radiograph for Subclinical TB Detection in ESRD and KT

Last updated: November 20, 2024
Sponsor: Mahidol University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hiv

Lung Disease

Treatment

N/A

Clinical Study ID

NCT06700876
NRCT9-5
  • Ages > 18
  • All Genders

Study Summary

This is an observational study among approximately 160 end-stage renal disease patients on renal replacement therapy and post-living donor or deceased donor kidney transplant recipients. Investigators aim to assess the proportion of positive IGRA associated with symptom development, sputum Xpert MTB/RIF assay, and chest radiograph to define latent TB infection and subclinical TB among ESKD and renal transplant patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. End-stage renal disease on renal replacement therapy (hemodialysis or peritonealdialysis) or status-post-living donor or deceased donor kidney transplantation

  2. Aged more than or equal 18 years

Exclusion

Exclusion Criteria:

  1. Positive PPD test or a previously documented positive PPD

  2. Active pulmonary or extrapulmonary tuberculosis

Study Design

Total Participants: 160
Study Start date:
August 06, 2024
Estimated Completion Date:
June 30, 2027

Study Description

Patients with chronic kidney disease and end-stage kidney disease (ESKD) are at risk of developing tuberculosis and are often delayed in diagnosis. Herein, investigators aim to assess the proportion of positive IGRA associated with symptom development, sputum Xpert MTB/RIF assay, and chest radiograph to define latent TB infection and subclinical TB among ESKD and renal transplant patients.

Connect with a study center

  • Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University

    Bangkok, 10400
    Thailand

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.